Impact of COVID-19 on lung transplant patients' respiratory function
Evolution of Respiratory Function in Lung Transplant Patients With Moderate to Severe SARS-Cov-2 Infection, Single-center Retrospective Study
This study looks at how moderate to severe COVID-19 affects the breathing ability of lung transplant patients to better understand their risks and health outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 75 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06490744 on ClinicalTrials.gov |
What this trial studies
This observational study examines how moderate to severe COVID-19 infection affects the respiratory function of lung transplant patients. It focuses on understanding the relationship between the severity of COVID-19 and the immunological status of these patients, who are at higher risk for respiratory complications. The study will analyze data from lung transplant patients diagnosed with COVID-19 and hospitalized at the University Hospitals of Strasbourg between March 2020 and December 2022. The findings may provide insights into the evolution of respiratory function in this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates include adult lung transplant patients diagnosed with COVID-19 and hospitalized at the University Hospitals of Strasbourg.
Not a fit: Patients who have expressed opposition to the reuse of their data for scientific research purposes will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the management and treatment strategies for lung transplant patients infected with COVID-19.
How similar studies have performed: While there have been studies on COVID-19 impacts on various populations, this specific focus on lung transplant patients is relatively novel and underexplored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient * Lung transplant patient (monopulmonary or bipulmonary) * Covid diagnosed by RT-PCR between March 1, 2020 and December 31, 2022 * Hospitalization at the University Hospitals of Strasbourg for COVID-19 * Patient followed in the context of their lung transplant at the University Hospitals of Strasbourg * Absence of written opposition in the subject's medical file to the reuse of their data for scientific research purposes. Exclusion Criteria: * Subject having expressed his opposition to the reuse of his data for scientific research purposes.
Where this trial is running
Strasbourg
- Service d'Anesthésie Réanimation - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Charles Ambroise TACQUARD, MD
- Email: charlesambroise.tacquard@chru-strasbourg.fr
- Phone: 33 3 69 55 16 08
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.